Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID A TESSLER

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1659359883
CMS profile
210347
Location
MESA, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$42,051.85

186 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 3 of 4; records 101–150 of 186 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID A TESSLER

NPI 1659359883 · CMS profile ID 210347

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

MESA, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 186 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1659359883?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID A TESSLER, NPI 1659359883, CMS profile ID 210347. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 186 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1659359883?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). DAVID A TESSLER, NPI 1659359883, CMS profile ID 210347. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 186 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1659359883?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
DAVID A TESSLER, NPI 1659359883, CMS profile ID 210347, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 186 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1659359883?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

186 matching records · $42,051.85 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 186 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 186.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Covis Pharma GmBH $30.8006/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 953399113 CMS
ABBVIE INC. $24.3806/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892513335 CMS
ABBVIE INC. $20.7906/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892513333 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $6.7806/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959968615 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $6.3406/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959569599 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $8.1506/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959798995 CMS
ABBVIE INC. $27.9206/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892513329 CMS
Ferring Pharmaceuticals Inc. $13.4106/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 875363447 CMS
Braintree Laboratories, Inc. $12.1106/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898421395 CMS
ABBVIE INC. $17.8806/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892513321 CMS
ABBVIE INC. $17.5506/01/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892513325 CMS
ABBVIE INC. $2,750.0005/31/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892513317 CMS
ABBVIE INC. $122.8105/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892513313 CMS
Regeneron Healthcare Solutions, Inc. $17.0605/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927443747 CMS
Ardelyx, Inc. $19.0105/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 925732819 CMS
ABBVIE INC. $25.8605/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892513311 CMS
ABBVIE INC. $102.0405/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892513307 CMS
Janssen Biotech, Inc. $15.1405/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885506647 CMS
ABBVIE INC. $23.4105/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892513305 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $12.0705/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959640757 CMS
Merck Sharp & Dohme LLC $15.7905/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944495583 CMS
ABBVIE INC. $25.5505/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892513301 CMS
ABBVIE INC. $21.8305/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892513299 CMS
PFIZER INC. $6.7404/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949112697 CMS
Merck Sharp & Dohme LLC $17.8004/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944486207 CMS
ABBVIE INC. $44.0004/26/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892513293 CMS
ABBVIE INC. $57.0604/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892513295 CMS
Baxter Healthcare $16.1304/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885132727 CMS
ABBVIE INC. $23.2004/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892513291 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $7.0504/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959772259 CMS
ABBVIE INC. $2,200.0004/20/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892513285 CMS
ABBVIE INC. $2,200.0004/20/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892513287 CMS
Gilead Sciences, Inc. $95.4004/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929481187 CMS
ABBVIE INC. $82.6404/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892513269 CMS
ABBVIE INC. $3.1204/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892513271 CMS
ABBVIE INC. $75.1504/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892513275 CMS
ABBVIE INC. $22.0304/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892513279 CMS
ABBVIE INC. $671.5804/09/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892513281 CMS
ABBVIE INC. $59.1704/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892513251 CMS
ABBVIE INC. $124.9104/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892513253 CMS
ABBVIE INC. $210.1504/08/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892513257 CMS
ABBVIE INC. $3.3004/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892513259 CMS
ABBVIE INC. $111.5604/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892513263 CMS
ABBVIE INC. $86.6104/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892513265 CMS
ABBVIE INC. $19.4104/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892513241 CMS
ABBVIE INC. $149.8804/07/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892513245 CMS
ABBVIE INC. $210.1504/07/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892513247 CMS
ABBVIE INC. $100.3904/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892513239 CMS
Ardelyx, Inc. $19.0404/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 925732817 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $9.1704/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959806877 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $16,402.63 83
PY2020 $5,983.36 81
PY2021 $20,983.26 130
PY2022 $42,051.85 186
PY2023 $43,945.94 149
PY2024 $32,485.87 169
PY2025 $29,109.85 193

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2020 Principal investigator $21,940.84 17

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

17 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $1,130.94 12/31/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double- Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 721316191
Principal investigator 1 Allergan, Inc. $1,233.90 12/31/2020 Non-covered Recipient Entity
CLINICAL RESEARCH ADVANTAGE INC
A 52-Week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-Controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants with moderately to Severely Active Crohn No dispute reported 06/30/2026 721318417
Principal investigator 1 Allergan, Inc. $86.00 10/01/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721301093
Principal investigator 1 Allergan, Inc. $700.00 08/11/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721289451
Principal investigator 1 Allergan, Inc. $86.00 08/04/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721288479
Principal investigator 1 Allergan, Inc. $86.00 07/23/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721286685
Principal investigator 1 Allergan, Inc. $86.00 07/23/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721286701
Principal investigator 1 Allergan, Inc. $86.00 07/23/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721287023
Principal investigator 1 Allergan, Inc. $86.00 07/23/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721287165
Principal investigator 1 Allergan, Inc. $86.00 07/21/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721285791
Principal investigator 1 Allergan, Inc. $86.00 07/14/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721283401
Principal investigator 1 Allergan, Inc. $401.00 07/09/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721283141
Principal investigator 1 Allergan, Inc. $700.00 06/25/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721282009
Principal investigator 1 Allergan, Inc. $8,036.00 04/01/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double- Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 721268265
Principal investigator 1 Allergan, Inc. $8,036.00 03/20/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 52-Week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-Controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants with moderately to Severely Active Croh No dispute reported 06/30/2026 721266425
Principal investigator 1 Allergan, Inc. $315.00 02/06/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721256025
Principal investigator 1 Allergan, Inc. $700.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721253501